Randomized clinical trials assessing the efficacy of neoadjuvant chemotherapy (NACT) for advanced epithelial ovarian cancer have predominantly included women with high-grade serous carcinomas. The response rate and oncological outcomes of NACT for malignant ovarian germ cell tumors (MOGCT) are poorly understood. This study aimed to examine the effects of NACT on women with MOGCT by conducting a systematic review of four public search engines. Fifteen studies were identified, and a further descriptive analysis was performed for 10 original articles. In those studies, most women were treated with a bleomycin, etoposide, and cisplatin regimen, and one to three cycles were used in most studies. Four studies comparing NACT and primary debulking surgery showed similar complete response rates (n= 2; pooled odds ratio [OR] 0.90, 95% confidence interval [CI] 0.15–5.27), comparable overall survival (n= 3; 87.0–100% versus 70.0–100%), disease-free survival (n= 3; 87.0–100% versus 70.0–100%), recurrence rate (n= 1; OR 3.50, 95%CI 0.38–32.50), and adverse events rate from chemotherapy between the groups. In conclusion, NACT may be considered for the management of MOGCT; however, possible candidates for NACT use and an ideal number of NACT cycles remain unknown. Further studies are warranted to validate the efficacy of NACT in advanced MOGCT patients.
评估新辅助化疗（NACT）对晚期上皮性卵巢癌疗效的随机临床试验主要纳入了高级别浆液性癌患者。目前对于NACT治疗恶性卵巢生殖细胞肿瘤（MOGCT）的缓解率及肿瘤学结局仍知之甚少。本研究旨在通过对四个公共搜索引擎进行系统综述，探讨NACT对MOGCT患者的影响。共筛选出15项研究，并对其中10篇原始文献进行了描述性分析。在这些研究中，大多数患者接受了博来霉素、依托泊苷和顺铂联合方案治疗，且多数研究采用1至3个周期化疗。四项比较NACT与初次肿瘤细胞减灭术的研究显示，两组在完全缓解率（n=2；合并比值比[OR] 0.90，95%置信区间[CI] 0.15–5.27）、总生存期（n=3；87.0–100%对比70.0–100%）、无病生存期（n=3；87.0–100%对比70.0–100%）、复发率（n=1；OR 3.50，95%CI 0.38–32.50）以及化疗相关不良事件发生率方面均具有可比性。综上所述，NACT可考虑用于MOGCT的治疗，但适用NACT的潜在人群及理想化疗周期数仍不明确，需要进一步研究验证NACT在晚期MOGCT患者中的疗效。
肿瘤(癌症)患者之家